How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors

por Jordan, B., Benesova, K., Hassel, J.C., Wick, W., Jordan, K.
Publicado 2021

Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases

por Uhrig, M., Sedlmair, M., Schlemmer, H.P., Hassel, J.C., Ganten, M.
Publicado 2013

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

por Hassel, J C, Sucker, A, Edler, L, Kurzen, H, Moll, I, Stresemann, C, Spieth, K, Mauch, C, Rass, K, Dummer, R, Schadendorf, D
Publicado 2010

Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy

por Hassel, J.C., Livingstone, E., Allam, J.P., Behre, H.M., Bojunga, J., Klein, H.H., Landsberg, J., Nawroth, F., Schüring, A., Susok, L., Thoms, K.M., Kiesel, L., Berking, C.
Publicado 2021

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

por Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Publicado 2016

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

por Kähler, Katharina C., Hüning, S., Nashan, D., Meiss, F., Rafei-Shamsabadi, D. A., Rissmann, H., Colapietro, C., Livingstone, E., Maul, L. V., Heppt, M., Hassel, J. C., Gutzmer, R., Loquai, C., Heinzerling, L., Sachse, M. M., Bohne, A. S., Moysig, L., Peters, W., Rusch, J., Blome, C.
Publicado 2023